NICE, the NHS, and cancer drugs
Cet article analyse les méthodologies utilisées au Royaume-Uni par le "National Institute for Health and Care Excellence" (NICE) pour évaluer l'intérêt et le rapport coût-efficacité des médicaments anticancéreux et aider aux recommandations de bonne pratique
NICE was established in 1999 to help the National Health Service (NHS) in England and Wales to improve outcomes for patients by providing evidence-based clinical practice guidance. Technology appraisal guidance evaluates the clinical and cost-effectiveness of new drugs, medical devices, and diagnostics and makes recommendations on their use. Between March 2000 and October 2017, 783 recommendations have been published. Cancer technologies constitute 41% of all published technology appraisals.
JAMA 2018